Granules India Ltd. announced its financial results for the second quarter ended September 30, 2026. The company reported a 20% year-over-year growth in revenue from operations, reaching INR 15,600 million. EBITDA increased by 21% YoY to INR 3,376 million, while Profit After Tax (PAT) saw a significant jump of 39% YoY to INR 1,818 million.
Granules India Announces Strong Q2 FY27 Financial Performance
Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the second quarter and half-year ended September 30, 2026. The company has reported robust year-over-year growth across key financial metrics.
Financial Highlights for Q2 FY27
Revenue from operations for the second quarter of FY27 stood at INR 15,600 million, marking a substantial 20% increase compared to the same period last year. EBITDA for the quarter was INR 3,376 million, up by 21% YoY. Profit Before Tax (PBT) grew by 38% YoY to INR 2,434 million. The company’s Profit After Tax (PAT) also demonstrated strong performance, increasing by 39% YoY to INR 1,818 million.
Operational Performance and Business Segments
The company’s revenue from operations in Q2FY27 grew by 20% YoY. Revenue share from North America was 72% in Q2FY27 compared to 76% in Q2FY26, while Europe’s share increased to 16% from 12% in Q2FY26. Key business segments contributing to revenue include Finished Dosages (FD) at 73%, Active Pharmaceuticals Ingredients (API) at 13%, Pharmaceutical Formulation Intermediates (PFI) at 10%, and Peptides CDMO at 3%.
Financial Position
The company closed the quarter with a net cash position of ₹8,280 million, a notable improvement from a net debt of ₹1,012 million in Q1 FY27. ROCE (Return on Capital Employed) remained strong at 17.6% in Q2FY27, consistent with FY26.
Chairman’s Commentary
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited, commented on the results, stating, “Our Quarterly revenue has crossed ₹1500 Cr in Q2 FY27 with EBITDA of ₹338 Cr, despite higher input and logistics costs from tensions in West Asia. Cost pressures will persist and we are working with customers to manage them with a lag. We filed two potential first-to-file ANDAs in H1, which makes it a total of three potential first to file ANDAs and continue to shift towards complex generics and peptide CDMO. With the balance warrant proceeds received, we hold net cash of ₹828 Cr to invest in R&D, manufacturing and quality”. He also mentioned the successful conclusion of a US FDA audit at the Gagillapur site.
Source: BSE
